Search Results - "van Dongen, Guus A."

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101) by Gaillard, Pieter J, Appeldoorn, Chantal C M, Dorland, Rick, van Kregten, Joan, Manca, Francesca, Vugts, Danielle J, Windhorst, Bert, van Dongen, Guus A M S, de Vries, Helga E, Maussang, David, van Tellingen, Olaf

“…Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the…”
Get full text

Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody by Wuensche, Thomas E., Stergiou, Natascha, Mes, Iris, Verlaan, Mariska, Kooijman, Esther J. M., Windhorst, Albert D., Jensen, Allan, Asuni, Ayodeji A., Bang-Andersen, Benny, van Dongen, Guus A. M. S., Vugts, Danielle J., Beaino, Wissam

“…Purpose In the emerging field of antibody treatments for neurodegenerative diseases, reliable tools are needed to evaluate new therapeutics, diagnose and…”
Get full text

The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells by van Rhenen, Anna, van Dongen, Guus A.M.S., Kelder, Angèle, Rombouts, Elwin J., Feller, Nicole, Moshaver, Bijan, Walsum, Marijke Stigter-van, Zweegman, Sonja, Ossenkoppele, Gert J., Jan Schuurhuis, Gerrit

“…In CD34+ acute myeloid leukemia (AML), the malignant stem cells reside in the CD38− compartment. We have shown before that the frequency of such CD34+CD38−…”
Get full text

Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging by Dubois, Ludwig J, Lieuwes, Natasja G, Janssen, Marco H. M, Peeters, Wenny J. M, Windhorst, Albert D, Walsh, Joseph C, Kolb, Hartmuth C, Öllers, Michel C, Bussink, Johan, van Dongen, Guus A. M. S, van der Kogel, Albert, Lambin, Philippe

“…Hypoxia has been shown to be an important microenvironmental parameter influencing tumor progression and treatment efficacy. Patient guidance for…”
Get full text

Good practices for 89Zr radiopharmaceutical production and quality control by Wuensche, Thomas Erik, Lyashchenko, Serge, van Dongen, Guus A. M. S., Vugts, Danielle

“…Background During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and…”
Get full text

State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET by Chomet, Marion, van Dongen, Guus A. M. S, Vugts, Danielle J

“…Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or antibody mimetics with radiometals is a prerequisite for immuno-PET…”
Get full text

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors by Pruis, Ilanah J, van Dongen, Guus A M S, Veldhuijzen van Zanten, Sophie E M

“…This review highlights the added value of PET imaging in Central Nervous System (CNS) tumors, which is a tool that has rapidly evolved from a merely diagnostic…”
Get full text

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor by Högnäsbacka, Antonia A., Poot, Alex J., Plisson, Christophe, Bergare, Jonas, Bonsall, David R., McCluskey, Stuart P., Wells, Lisa A., Kooijman, Esther, Schuit, Robert C., Verlaan, Mariska, Beaino, Wissam, van Dongen, Guus A. M. S., Vugts, Danielle J., Elmore, Charles S., Passchier, Jan, Windhorst, Albert D.

“…Background Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine kinase…”
Get full text

Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET by Wijngaarden, Jessica E., Jauw, Yvonne W. S., Zwezerijnen, Gerben J. C., de Wit-van der Veen, Berlinda J., Vugts, Daniëlle J., Zijlstra, Josée M., van Dongen, Guus A. M. S., Boellaard, Ronald, Menke-van der Houven van Oordt, C. Willemien, Huisman, Marc C.

“…Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89 Zr-mAb uptake on PET. Target-specific…”
Get full text

How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans by Wijngaarden, Jessica E., Ahbari, Amina, Pouw, Johanna E. E., Greuter, Henri N. J. M., Bahce, Idris, Zwezerijnen, Gerben J. C., Vugts, Daniëlle J., van Dongen, Guus A. M. S., Boellaard, Ronald, Menke-van der Houven van Oordt, C. Willemien, Huisman, Marc C.

“…Background PET scans using zirconium-89 labelled monoclonal antibodies ( 89 Zr-mAbs), known as 89 Zr-immuno-PET, are made to measure uptake in tumour and organ…”
Get full text

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor by Högnäsbacka, Antonia, Poot, Alex J, Vugts, Danielle J, van Dongen, Guus A M S, Windhorst, Albert D

“…Multiple small molecule PET tracers have been developed for the imaging of the epidermal growth factor receptor (EGFR). These tracers target the tyrosine…”
Get full text

A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth by Roovers, Rob C., Vosjan, Maria J.W.D., Laeremans, Toon, el Khoulati, Rachid, de Bruin, Renée C.G., Ferguson, Kathryn M., Verkleij, Arie J., van Dongen, Guus A.M.S., van Bergen en Henegouwen, Paul M.P.

“…The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for antibody‐based therapy. At present, several anti‐EGFR monoclonal…”
Get full text

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example by Huisman, Marc C., Menke-van der Houven van Oordt, C. Willemien, Zijlstra, Josée M., Hoekstra, Otto S., Boellaard, Ronald, van Dongen, Guus A. M. S., Shah, Dhaval K., Jauw, Yvonne W. S.

“…Background 89 Zirconium-immuno-positron emission tomography ( 89 Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy. We aim…”
Get full text

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging by Perk, Lars R., Vosjan, Maria J. W. D., Visser, Gerard W. M., Budde, Marianne, Jurek, Paul, Kiefer, Garry E., van Dongen, Guus A. M. S.

“…Purpose Immuno-PET is an emerging imaging tool for the selection of high potential antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89…”
Get full text

Immuno-PET Imaging of Atherosclerotic Plaques with [ 89 Zr]Zr-Anti-CD40 mAb-Proof of Concept by Poels, Kikkie, Schreurs, Maxime, Jansen, Matthijs, Vugts, Danielle J, Seijkens, Tom T P, van Dongen, Guus A M S, Lutgens, Esther, Beaino, Wissam

“…Non-invasive imaging of atherosclerosis can help in the identification of vulnerable plaque lesions. CD40 is a co-stimulatory molecule present on various…”
Get full text

Noise sensitivity of 89Zr-Immuno-PET radiomics based on count-reduced clinical images by Somasundaram, Ananthi, García, David Vállez, Pfaehler, Elisabeth, Jauw, Yvonne W. S., Zijlstra, Josée M., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, Willemien C., Huisman, Marc C., de Vries, Elisabeth G. E., Boellaard, Ronald

“…Purpose Low photon count in 89 Zr-Immuno-PET results in images with a low signal-to-noise ratio (SNR). Since PET radiomics are sensitive to noise, this study…”
Get full text

Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake by Wijngaarden, Jessica E., Huisman, Marc C., Jauw, Yvonne W. S., van Dongen, Guus A. M. S., Greuter, Henri N. J. M., Schuit, Robert C., Cleveland, Matthew, Gootjes, Elske C., Vugts, Daniëlle J., Menke-van der Houven van Oordt, C. Willemien, Boellaard, Ronald

“…Purpose Positron emission tomography imaging of zirconium-89-labelled monoclonal antibodies ( 89 Zr-Immuno-PET) allows for visualisation and quantification of…”
Get full text

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus by TIJINK, Bernard M, BUTER, Jan, DE BREE, Remco, GIACCONE, Giuseppe, LANG, Margreet S, STAAB, Alexander, LEEMANS, C. Rene, VAN DONGEN, Guus A. M. S

“…Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine. Bivatuzumab is a humanized monoclonal…”
Get full text

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET by van Dongen, Guus A. M. S., Poot, Alex J., Vugts, Danielle J.

“…During the last decade, the discovery of critical tumor targets has boosted the design of targeted therapeutic agents with monoclonal antibodies (mAbs) and…”
Get full text

Head-to-head comparison of DFO and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET by Chomet, Marion, Schreurs, Maxime, Bolijn, Maria J., Verlaan, Mariska, Beaino, Wissam, Brown, Kari, Poot, Alex J., Windhorst, Albert D., Gill, Herman, Marik, Jan, Williams, Simon, Cowell, Joseph, Gasser, Gilles, Mindt, Thomas L., van Dongen, Guus A. M. S, Vugts, Danielle J.

“…Purpose Almost all radiolabellings of antibodies with 89 Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted…”
Get full text